Indeed, there is no persuasive evidence that ACE inhibitors, ARBs, aldosterone antagonists, or b-blockers in survivors of adult cancers improve survival or quality of life when used for either primary or secondary prevention [44]. This evidence concerns the gene ACE and cancer.